Search
My Cart

Arecoline HBr

SKU
A-2553
  • CAS:300-08-3
  • Formula:C8H13NO2•HBr
  • MW:236.108 Da
  • Appearance:Solid powder
  • Purity:>98% (TLC); NMR (Conforms)

2

0

0

SDS
CofA
Product Name Qty
Arecoline HBr
1 g
$101.99
Arecoline HBr
500 mg
$66.30
Arecoline HBr
5 g
$346.80
Add to Compare Email
Loading...

Description

Arecoline Hydrobromide (Arecoline HBr) is a betel nut alkaloid. It is an agonist of both muscarinic and nicotinic acetylcholine receptors. Because it is a parasympathomimetic drug, it has been used as a euphoriant and shown to improve memory and learning ability. It may prove to be useful in treating dementia. It is also reported cytotoxic for endothelial cells and fibroblasts.

It has shown to activate critical genes related to β-cell regeneration, such as pancreatic and duodenal homeobox 1(pdx-1) and glucose transporter 2(GLUT-2) in rats. It can thus be believed that arecoline is effective in improving the detrimental effects caused by insulin deficiency in rats with type 1 diabetes. 


Applications

• Parasympathomimetic drug

• Cancer treatment

• Diabetes management

• Veterinary practices

 

References

• "A Protective Role of Arecoline Hydrobromide In Experimentally Induced Male Diabetic Rats" 

• "Arecoline is cytotoxic for human endothelial cells"

More Information
Alternate Name/Synonyms
Taeniolin; Arecoline hydrobromide; Arekolinhydrobromid
SKU
A-2553
CAS #
300-08-3
Chemical Name
methyl 1-methyl-3,6-dihydro-2H-pyridine-5-carboxylate;hydrobromide
Chemical Formula
C8H13NO2•HBr
Molecular Weight
236.108 Da
Appearance
Solid powder
Purity
>98% (TLC); NMR (Conforms)
Solubility
May be dissolved in water (50 mg/mL)
Melting Point
171-176°C
Storage Temp
Room temperature
THERAPEUTIC AREA
Neurodegenrative Diseases
USE
Arecoline HBr is a covalent inhibitor of ACAT1 which binds to ACAT1 tetramers, but not to ACAT2 and DLAT. Study of mice with Arecoline HBr has resulted in a dose-dependent reduction in tumor mass. As it also seems to be effective in improving learning ability, it is suggested as a treatment of Alzheimer's disease possibly due to its carcinogenic properties.
MDL NUMBER
MFCD00039041
CHEMACX
X1033035-5
INCHI
InChI=1S/C8H13NO2.BrH/c1-9-5-3-4-7(6-9)8(10)11-2;/h4H,3,5-6H2,1-2H3;1H
SMILES
CN1CCC=C(C1)C(=O)OC.Br
RTECS
QT2275000
UN #'S
UN 2811
PACKING GROUP
III
Handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs.
GHS PICTOGRAMS
Handling Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs.
UN #'S UN 2811
Packing Group III
To Top